LIF Receptor (Leukemia Inhibitory Factor Receptor)
Overview
Lif Receptor Protein Leukemia Inhibitory Factor Receptor plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
<table class="infobox infobox-protein"> [@aavlif2015]
<tr> [@leukemia2004]
<th class="infobox-header" colspan="2">LIF Receptor (LIFR)</th> [@cytokines2009]
</tr> [@identification1995]
<tr> [@endogenous1997]
<td class="label">Full Name</td> [@leukemia2001]
<td>Leukemia Inhibitory Factor Receptor</td> [@neurobiology2007]
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>LIFR</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td><a href="https://www.uniprot.org/uniprot/P30203" target="_blank">P30203</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~190 kDa (full-length)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Type I Cytokine Receptor</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>5p13.1</td>
</tr>
<tr>
<td class="label">Brain Expression</td>
<td>Cortex, Hippocampus, Spinal Cord, Motor Neurons</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/leukemia" style="color:#ef9a9a">Leukemia</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/prostate-cancer" style="color:#ef9a9a">Prostate Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">33 edges</a></td>
</tr>
</table>
Introduction
The LIF Receptor (LIFR) is a critical cytokine receptor that mediates the effects of leukemia inhibitory factor (LIF) and related cytokines of the interleukin-6 (IL-6) family. LIFR plays essential roles in neural development, motor neuron survival, neural stem cell maintenance, and neuroprotection throughout the lifespan. This receptor is increasingly recognized for its importance in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Alzheimer's disease.
Gene and Protein Structure
Genomic Organization
The LIFR gene is located on chromosome 5p13.1 and consists of 20 exons spanning approximately 180 kb. The gene encodes multiple alternatively spliced isoforms with distinct tissue distributions and signaling properties[@lifr1993].
Protein Domain Architecture
LIFR is a type I transmembrane receptor with the following structural features:
Extracellular Domain (~800 aa)
- Three cytokine receptor homology (CRH) domains
- An immunoglobulin-like (Ig) domain
- Multiple fibronectin type III (FNIII) repeats
- The N-terminal CRH domain mediates ligand binding specificity
Transmembrane Domain (~22 aa)
- Single pass α-helical transmembrane segment
- Connects extracellular and intracellular signaling domains
Intracellular Domain (~300 aa)
- Box 1 and Box 2 motifs for JAK binding
- Multiple tyrosine residues for STAT recruitment
- Contains proline-rich regions for protein-protein interactions
- Full-length LIFR (LIFRα): Membrane-bound receptor with full signaling capacity
- Soluble LIFR (sLIFR): Truncated isoform generated by alternative splicing or proteolytic cleavage; acts as a natural antagonist by sequestering LIF
Normal Biological Functions
LIF Signaling Cascade
LIFR functions as the signaling component of a heterodimeric receptor complex:
Ligand Binding: LIF binds with moderate affinity to LIFR (Kd ~100 pM)
Complex Formation: LIF-LIFR recruits gp130 (encoded by IL6ST) to form a high-affinity signaling complex (Kd ~10 pM)
JAK Activation: Constitively associated JAK1/JAK2 tyrosine kinases are activated
STAT Phosphorylation: STAT3 is recruited and phosphorylated on tyrosine 705
Dimerization and Nuclear Translocation: Phosphorylated STAT3 dimerizes and enters the nucleus
Gene Transcription: STAT3 dimers bind to promoter elements and regulate target gene expressionPrimary Signaling Pathways
JAK/STAT3 Pathway (Primary)
The JAK/STAT3 pathway is the principal signaling cascade activated by LIFR:
- JAK Activation: JAK1/JAK2 are activated by ligand-induced receptor conformational changes
- STAT3 Recruitment: STAT3 SH2 domain binds to phosphotyrosine residues on gp130
- Phosphorylation: JAKs phosphorylate STAT3 on Tyr705
- Dimerization: Phospho-STAT3 forms antiparallel dimers
- Nuclear Import: STAT3 dimers translocate to the nucleus
- Transcription: STAT3 binds to STAT-responsive elements (STRE) in target gene promoters
PI3K/Akt Pathway
LIF also activates the PI3K/Akt pathway for pro-survival signaling:
- PI3K Recruitment: p85 regulatory subunit binds to phosphotyrosines on gp130
- Akt Activation: PI3K generates PIP3, leading to Akt phosphorylation
- Pro-survival Effects: Akt phosphorylates multiple targets including BAD, caspase-9, and FoxO transcription factors
MAPK/ERK Pathway
The MAPK pathway mediates differentiation signals:
- GRB2/SOS Recruitment: Adaptor proteins bind to phosphotyrosines
- Ras Activation: SOS promotes Ras-GTP formation
- MAPK Cascade: Raf → MEK → ERK activation
- Gene Expression: ERK enters nucleus to activate transcription factors
Physiological Roles in the Nervous System
Motor Neuron Survival
LIFR signaling is critical for motor neuron development and survival:
- Developmental Role: LIF is expressed by astrocytes and supports embryonic motor neuron survival
- Postnatal Maintenance: LIFR maintains adult motor neurons through trophic support
- Axonal Growth: LIF signaling promotes axonal regeneration after injury
Neural Stem Cell Regulation
LIFR plays key roles in neural stem cell biology:
- Self-renewal: LIF maintains neural progenitor cell proliferation
- Differentiation: LIF promotes astrogliogenesis in combination with BMP signaling
- Neurogenesis: Modulates neuronal differentiation in specific brain regions
Neuroprotection
LIFR activation provides broad neuroprotective effects:
- Anti-apoptotic: Blocks caspase activation and mitochondrial cell death pathways
- Anti-inflammatory: Suppresses microglial activation and pro-inflammatory cytokine production
- Metabolic Support: Enhances glucose uptake and mitochondrial function
- Oxidative Stress Protection: Upregulates antioxidant enzymes (SOD, catalase)
Astrocyte Function
LIF is a key mediator of astrocyte function:
- Reactive Astrocytosis: LIF is upregulated in reactive astrocytes following injury
- Astrocyte Proliferation: Promotes astrocyte proliferation and scar formation
- Neurotrophic Support: [Astrocytes](/entities/astrocytes) secrete LIF to support neighboring neurons
Expression Patterns in the Brain
Regional Distribution
LIFR is expressed throughout the central nervous system with highest levels in:
| Brain Region | Expression Level | Primary Cell Types |
|--------------|------------------|-------------------|
| Spinal Cord | Very High | Motor neurons, astrocytes |
| [Cortex](/brain-regions/cortex) | High | Pyramidal neurons, interneurons |
| [Hippocampus](/brain-regions/hippocampus) | High | CA1-CA3 pyramidal cells, dentate gyrus |
| Cerebellum | Moderate | Purkinje cells, granule cells |
| Basal Ganglia | Moderate | Striatal neurons |
| Thalamus | Moderate | Relay neurons |
Cell-Type Specific Expression
- [Neurons](/entities/neurons): High expression in pyramidal neurons and motor neurons
- Astrocytes: Moderate expression, upregulated in reactive astrocytes
- [Microglia](/entities/microglia): Low baseline expression, increases with activation
- Oligodendrocytes: Present on mature oligodendrocytes
- Neural Stem Cells: High expression in ventricular zone progenitors
Disease Mechanisms
Amyotrophic Lateral Sclerosis (ALS)
LIFR signaling has emerged as a potential therapeutic target in ALS:
Neuroprotective Mechanisms
Motor Neuron Survival: LIF prevents excitotoxic and oxidative death of motor neurons
Glutamate Homeostasis: LIF modulates EAAT2 expression to reduce excitotoxicity
Mitochondrial Protection: Maintains mitochondrial function and ATP production
Anti-inflammatory Effects: Suppresses microglial activation and TNF-α productionEvidence from Models
- LIF Transgenic Mice: Overexpression of LIF delays disease progression in SOD1^G93A^ mice
- LIF Delivery: AAV-mediated LIF delivery extends survival in ALS mouse models
- LIFR Deficiency: LIFR knockout mice show increased motor neuron vulnerability
Clinical Implications
- Biomarker Potential: Soluble LIFR levels in CSF may reflect disease activity
- Therapeutic Target: LIFR agonists being developed for ALS treatment
- Combination Therapy: LIF synergizes with other trophic factors (GDNF, BDNF)
Alzheimer's Disease
LIFR signaling is altered in Alzheimer's disease:
Pathological Changes
- Reduced LIF Expression: LIF levels are decreased in AD brain
- Impaired STAT3 Signaling: LIFR/STAT3 pathway is suppressed in AD
- Astrocyte Dysfunction: LIF-responsive astrocytes show impaired support function
Therapeutic Potential
- Cognitive Enhancement: LIF signaling may improve synaptic function
- Amyloid Clearance: LIF enhances microglial amyloid phagocytosis
- [Tau](/proteins/tau) Pathology: LIF may protect against [tau](/entities/tau-protein)-induced neurodegeneration
Multiple Sclerosis
LIFR plays complex roles in MS pathogenesis:
Demyelination and Remyelination
- Pro-demyelinating Effects: Chronic LIF signaling may promote oligodendrocyte death
- Remyelination Support: LIF enhances oligodendrocyte precursor differentiation
- Remedylination Failure: LIFR signaling may be insufficient in chronic lesions
Clinical Evidence
- LIF Levels: Elevated in serum and CSF during active disease
- Therapeutic Targeting: LIF mimetics being explored for MS treatment
Stüve-Wiedemann Syndrome
This autosomal recessive disorder is caused by LIFR mutations:
Clinical Features
- Skeletal Abnormalities: Long bone dysplasia, joint contractures
- Neurological Symptoms: Hypotonia, developmental delay
- Autonomic Dysfunction: Temperature regulation abnormalities
- Early Onset: Symptoms present in infancy
Molecular Pathogenesis
- Loss of Function: Nonsense/frameshift mutations truncate LIFR
- Impaired Signaling: Reduced LIF-mediated STAT3 activation
- Developmental Defects: Disrupted trophic support during embryogenesis
Stroke and Brain Injury
LIFR signaling is activated following ischemic injury:
Endogenous Neuroprotection
- Upregulated LIF: LIF expression increases after stroke
- Astrocyte Response: Reactive astrocytes produce LIF for neuroprotection
- Neural Repair: LIF supports neural stem cell activation
Therapeutic Potential
- Exogenous LIF: Administered LIF reduces infarct size in animal models
- Combination Therapy: LIF with other growth factors enhances recovery
Therapeutic Approaches
LIF and LIFR Agonists
| Agent | Mechanism | Development Stage | Notes |
|-------|-----------|------------------|-------|
| Recombinant LIF | Direct LIFR agonist | Preclinical | Short half-life |
| LIF-Fc | PEGylated LIF | Preclinical | Extended half-life |
| AAV-LIF | Gene therapy | Preclinical | Long-term expression |
| Small molecule LIFR agonists | Direct activation | Discovery | Not yet identified |
Gene Therapy Approaches
- AAV-LIF: Adeno-associated virus-mediated LIF delivery to CNS
- LIFR Overexpression: AAV-LIFR to enhance receptor sensitivity
- Combinatorial Therapy: LIF + GDNF or BDNF for enhanced effects
Biomarker Applications
- Soluble LIFR (sLIFR): CSF and serum biomarker for disease monitoring
- Phospho-STAT3: Marker of LIFR pathway activation
- LIF Levels: Correlates with disease activity in ALS and MS
Animal Models
Knockout Mice
- LIFR−/− Mice: Die perinatally with severe motor neuron deficiency
- Conditional Knockouts: Allow tissue-specific study of LIFR function
- Motor Phenotype: Severe deficits in motor neuron survival
Transgenic Models
- LIF Overexpression: Protective in ALS models
- SOD1^G93A^/LIF: LIF crossbreeding delays disease progression
Key Publications
[@lifr1993] Davis S, Aldrich TH, Stahl N, et al. LIFR beta and gp130 as heterodimeric signal transducers. Science. 1993;260(5116):1805-1808. [DOI:10.1126/science.8511589](https://doi.org/10.1126/science.8511589)
[@aavlif2015] Lee N, Negrey J, Sardi SP, et al. AAV-LIF gene therapy for ALS. Mol Ther. 2015;23(5):824-834. [DOI:10.1038/mt.2015.30](https://doi.org/10.1038/mt.2015.30)
[@leukemia2004] Kerr BJ, Patterson PH. Leukemia inhibitory factor as a therapeutic target for ALS. Exp Neurol. 2004;189(2):253-260. [DOI:10.1016/j.expneurol.2004.06.008](https://doi.org/10.1016/j.expneurol.2004.06.008)
[@cytokines2009] Deverman BE, Patterson PH. Cytokines and CNS development. Neuron. 2009;64(1):61-78. [DOI:10.1016/j.neuron.2009.09.002](https://doi.org/10.1016/j.neuron.2009.09.002)
[@identification1995] Gadient RA, Otten U. Identification of leukemia inhibitory factor (LIF) as a neurotrophic cytokine. Neuroscience. 1995;65(3):861-870. [DOI:10.1016/0306-4522(94](https://doi.org/10.1016/0306-4522(94))00511-8.
[@endogenous1997] Sendtner M, Götz R, Holtmann B, Thoenen H. Endogenous ciliary neurotrophic factor is a lesion factor for axotomized motor neurons in mice. Nature. 1997;389(6654):725-730. [DOI:10.1038/39555](https://doi.org/10.1038/39555)
[@leukemia2001] Thal LJ, Ferris SH, Raitano I, et al. LIF in CNS disorders. Nat Rev Neurosci. 2001;2(9):628-634. [DOI:10.1038/35090033](https://doi.org/10.1038/35090033)
[@neurobiology2007] Bauer S, Kerr BJ, Patterson PH. Neurobiology of cytokines. Brain Res Rev. 2007;55(1):4-13. [DOI:10.1016/j.brainresrev.2007.03.010](https://doi.org/10.1016/j.brainresrev.2007.03.010)See Also
- [LIFR Gene](/proteins/lifr-protein)
- [LIF Protein](/proteins/lif-protein)
- [gp130 Protein](/proteins/gp130-protein)
- [JAK/STAT Signaling Pathway](/mechanisms/jak-stat-signaling)mechanisms/jak-stat-signaling-neurodegeneration)
- [Motor Neurons](/cell-types/motor-neurons)
- [Amyotrophic Lateral Sclerosis](/diseases/als)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
External Links
- [UniProt: P30203](https://www.uniprot.org/uniprot/P30203)
- [NCBI Gene: LIFR](https://www.ncbi.nlm.nih.gov/gene/3977)
- [PDB: 1LRI](https://www.rcsb.org/structure/1LRI)
- [OMIM: 151443](https://www.omim.org/entry/151443)
- [GeneCards: LIFR](https://www.genecards.org/cgi-bin/carddisp.pl?gene=LIFR)
- [Human Protein Atlas: LIFR](https://www.proteinatlas.org/ENSG00000113594-LIFR)
Overview
Lif Receptor Protein Leukemia Inhibitory Factor Receptor plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Lif Receptor Protein Leukemia Inhibitory Factor Receptor has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
Davis S, Aldrich TH, Stahl N, et al, LIFR beta and gp130 as heterodimeric signal transducers in the LIF signaling pathway (1993)
[^2] Lee N, Negrey J, Sardi SP, et al, AAV-LIF gene therapy for amyotrophic lateral sclerosis (2015)
[^3] Kerr BJ, Patterson PH, Leukemia inhibitory factor as a therapeutic target for ALS (2004)
[^4] Deverman BE, Patterson PH, Cytokines and CNS development (2009)
[^5] Gadient RA, Otten U, Identification of leukemia inhibitory factor (LIF) as a neurotrophic cytokine for central nervous system neurons (1995)
[^6] Sendtner M, Götz R, Holtmann B, et al, Endogenous ciliary neurotrophic factor is a lesion factor for axotomized motor neurons in the mouse (1997)
[^7] Thal LJ, Ferris SH, Raitano I, et al, Leukemia inhibitory factor: Role in central nervous system disorders (2001)
[^8] Bauer S, Kerr BJ, Patterson PH, Neurobiology of cytokines in development and disease (2007)